Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure
Phänotypisierung von Patient:innen mit chronisch obstruktiver Lungenerkrankung und Herzinsuffizienz
ESC Heart Failure · 01.04.2025 · 12 (2) · 900-911
DOI: 10.1002/ehf2.15127 ↗Auf einen Blick
Bei HF-Patient:innen war COPD mit höherer Morbidität/Mortalität verbunden und bei erhaltener EF häufiger. Die Prävalenz war bei HFpEF am höchsten.
Fragestellung
Welche Prävalenz, Patientenprofile und Outcomes sind bei COPD über das EF-Spektrum der Herzinsuffizienz hinweg mit COPD assoziiert?
Methode
Patient:innen aus dem schwedischen HF-Register (2005 bis 2021); multivariable logistische Regression für Merkmale, Cox-Regression für Outcomes.
Ergebnisse
COPD-Prävalenz 13 %; HFpEF 16 %, HFmrEF 12 %, HFrEF 11 %. COPD war mit 15 % höherem Risiko für CV-Tod/HF-Hospitalisierung assoziiert: HR 1,15 (95 %-KI 1,11–1,18).
Schlussfolgerung der Autor:innen
COPD trat bei jedem achten HF-Patienten auf, häufiger bei erhaltener EF. Betroffene hatten schwerere HF, mehr Komorbiditäten und schlechtere Outcomes unabhängig von der EF.
Kernaussagen
- COPD-Prävalenz bei HF: 13 %
- Höchste Prävalenz bei HFpEF: 16 %
- COPD: HR 1,15 (95 %-KI 1,11–1,18) für CV-Tod/HF-Hospitalisierung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 07.11.2024. Verfasst von Peter Moritz Becher und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Heart Failure, Registries, Stroke Volume. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Heart and Lung Foundation, European Union AFFECT-AF, MAESTRIA.
Themen: COPD, Herzinsuffizienz
Abstract (Originalsprache)
Aims
Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are prevalent comorbidities associated with significant morbidity/mortality. We assessed prevalence of, patient profiles and outcomes associated with COPD across the ejection fraction (EF) spectrum.
Methods
HF patients enrolled in the Swedish HF registry between 2005 and 2021 were considered. Multivariable logistic regression models were fitted to assess patient characteristics independently associated with COPD and Cox regression models for investigating the associations between COPD and outcomes, that is, morbidity/mortality.
Results
Among 97 904 HF patients, COPD prevalence was 13%, highest in HF with preserved EF [HFpEF: 16%, HF with mildly reduced EF (HFmrEF): 12%, HF with reduced EF (HFrEF): 11%]. Key patient characteristics independently associated with a diagnosis of COPD included higher EF, female sex, smoking, obstructive sleep disorder, peripheral artery disease, a lower educational level, more severe HF, more likely mineralocorticoid receptor antagonist and diuretic use but less likely use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin-receptor-neprilysin inhibitors (not in HFrEF), beta-blockers, HF device therapies, and follow-up in HF nurse-led clinics. COPD was independently associated with a 15% higher risk of cardiovascular (CV) death/HF hospitalization [hazard ratio: 1.15 (95% confidence interval: 1.11–1.18)], CV death, non-CV death, all-cause death and HF hospitalizations, regardless of EF.
Conclusions
COPD was present in every eight patient with HF, and more common with preserved EF. Patients with COPD had more severe HF, heavier comorbidity burden and worse morbidity/mortality regardless of EF. Our results call for improved diagnostic and management strategies in patients with HF and COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
- German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
- Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden.
- Department of Cardiology (Clinic III for Internal Medicine) and Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of Cologne, Cologne, Germany.
- Heart and Vascular and Neurology Theme, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- Swedish Heart and Lung Foundation
- European Union AFFECT-AF
- MAESTRIA
- German Center for Cardiovascular Research supported by the German Ministry of Education and Research
- German Research Foundation
- Leducq Foundation
- British Heart Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Becher, P. M., Lindberg, F., Benson, L., Hage, C., Dahlström, U., Rosenkranz, S., Cosentino, F., Rosano, G. M. C., Blankenberg, S., Kirchhof, P., Braunschweig, F., Lund, L. H., & Savarese, G. (2025). Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure. ESC Heart Failure, 12(2), 900-911. https://doi.org/10.1002/ehf2.15127
Vancouver
Becher PM, Lindberg F, Benson L, Hage C, Dahlström U, Rosenkranz S, et al. Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure. ESC Heart Failure. 2025;12(2):900-911. doi:10.1002/ehf2.15127
BibTeX
@article{Becher2025,
author = {Becher, Peter Moritz and Lindberg, Felix and Benson, Lina and Hage, Camilla and Dahlström, Ulf and Rosenkranz, Stephan and Cosentino, Francesco and Rosano, Giuseppe M C and Blankenberg, Stefan and Kirchhof, Paulus and Braunschweig, Frieder and Lund, Lars H and Savarese, Gianluigi},
title = {Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {2},
pages = {900--911},
doi = {10.1002/ehf2.15127}
}
EUVIMED